Introduction {#S1}
============

Human somatic tumorigenesis is believed to initiate with a single genetic mutation in a cancer gene, with progressive accumulation of additional genetic alterations that confer a selective growth advantage on the mutant cell ([@R15]). A notable feature of this multistep model of carcinogenesis is the occurrence of a preferred (but not absolute) order in which these genetic mutations accumulate during cancer progression ([@R15]; [@R50]). In human colorectal carcinomas where defined histopathological stages are easily recognizable and accessible, this notion could be examined ([@R15]). However, other tumors such as prostate cancer, are notoriously heterogeneous and have precursor lesions that are not as well defined ([@R3],; [@R8]; [@R19]; [@R44]). Some have suggested that prostate cancer heterogeneity may be due to an underlying "field effect" which sensitizes wide swathes of tissue to transformation without the presence of an obvious histological abnormality, a phenomenon known as field cancerization ([@R41]). This complexity of the human disease makes the use of accurate animal models an attractive approach to define tumor initiation and multistep progression in prostate cancer.

To begin to address these issues, we used the *Z-MYC* mouse ([@R37]) which contains a latent, Cre-activatable *c-MYC* allele which when combined with a prostate-specific Cre allele (*PbCre4*), yields a novel mouse model of c-MYC-initiated prostate cancer that recapitulates various salient features of the human disease ([@R26]). In the *PBCre4;Z-MYC* model, we have shown that c-MYC is induced focally in the prostatic luminal epithelial cells. Notably, in a significant fraction of these mice, c-MYC expression leads to the expansion of "fields" of c-MYC-positive cells without eliciting any obvious pathology ([@R26]). However, c-MYC expression sensitizes the prostate cells to the transforming effects of additional mutations. To examine tumor progression in this model, we have generated *Pten/p53* compound mutant mice and examined loss of gene copy number in microdissected c-MYC-expressing prostate lesions. The genes that form the basis for this mouse model are relevant to human prostate cancer. c-MYC overexpression is an early event in prostate cancer, with recent studies indicating overexpression in up to \~76% of prostatic intraepithelial neoplasia (PIN) lesions ([@R22]), while alterations in *PTEN* and *P53* have been observed in human prostate cancer with varying frequencies ([@R4]; [@R5]; [@R6]; [@R10]; [@R11]; [@R12]; [@R13]; [@R16]; [@R17]; [@R18]; [@R20]; [@R23]; [@R27]; [@R28]; [@R29]; [@R30]; [@R32]; [@R33]; [@R34]; [@R36]; [@R39]; [@R40]; [@R42]; [@R45]; [@R48]; [@R51]). However, there has been limited analysis of the rates of mutation in *PTEN* and *P53* in the same tumor, and their relation to progression. Our analysis of c-MYC-initiated mouse prostate tumors allowed examination of alterations in *Pten* versus *p53* during tumor progression, which appears to be dictated by the molecular interaction between the c-MYC, Pten and p53 pathways.

Materials and Methods {#S2}
=====================

Animals {#S3}
-------

*Z-MYC*, *PbCre4*, *Pten^f/f^* and *p53^f/f^* mice on B6/129 background have been described previously ([@R21]; [@R25]; [@R26]; [@R37]; [@R49]). *p53^f/f^* and *Pten^f/f^* mice were obtained from MMHCC, Frederick. *PbCre4;p53^f/+^*, *PbCre4;p53^f/f^*, *PbCre4;Z-MYC;p53^f/+^* and *PbCre4;Z-MYC;p53^f/f^* mice were generated using a similar strategy to that described for generating *PbCre4/Z-MYC/Pten^f/f^* compound mutant mice ([@R26]). To generate *PbCre4;Pten^f/+^;p53^f/+^*, *PbCre4;Pten^f/f^;p53^f/+^*, *PbCre4;Pten^f/+^;p53^f/f^*, *PbCre4;Z-MYC;Pten^f/+^;p53^f/+^*, *PbCre4;Z-MYC;Pten^f/f^;p53^f/+^*, *PbCre4;Z-MYC;Pten^f/+^;p53^f/f^* mice, we first generated *PbCre4;Pten^f/f^;p53^f/f^* males and *Z-MYC;Pten^f/+^;p53^f/+^* females and these were further crossed. Animal care and experiments were carried out according to the protocols approved by the Institutional Animal Care and Use Committees at Vanderbilt University.

Histology and immunohistochemical analyses {#S4}
------------------------------------------

Mouse prostate tissues were prepared as described ([@R2]) and histopathology was evaluated by SAA and IAE based on published criteria ([@R31]). Immunohistochemical analyses were performed as described ([@R1])([@R2]) and the following antibodies were used (when indicated as TSA, Tyramide Signal Amplification (Perkin Elmer) was applied): anti-c-MYC (rabbit, 1:15,000 with TSA, Santa Cruz Biotechnology), anti-α-smooth muscle actin (SMA) (mouse, 1:2000, Sigma), anti-Pten (rabbit, 1:200 with TSA, Cell Signaling), anti-Synaptophysin (mouse, 1:1000, BD Biosciences), anti-activated Caspase 3 (rabbit, 1:500, Cell Signaling), anti-phospho-Histone H3 (rabbit, 1:500, Upstate), anti-p53 (rabbit, 1:5000 with TSA, Santa Cruz Biotechnology) and anti-androgen receptor (AR) (rabbit, 1:500, Santa Cruz Biotechnology). Double stains with two antibodies of same species are described previously ([@R26]). 3--4 tissue samples were used for the quantitation of proliferation and apoptosis using anti-phospho-Histone H3 and anti-activated Caspase 3 antibodies. Nuclei were stained with DAPI (Vector Laboratories).

Laser capture microdissection (LCM) and DNA isolation {#S5}
-----------------------------------------------------

LCM was performed on PixCell II Laser Capture Microdissection System (MDS) using CapSure Macro LCM Caps (MDS) and DNA extraction was followed according to manufacturer\'s instruction (PicoPure DNA extraction kit, MDS). Immunostaining for c-MYC and Pten on adjacent sections were used to guide LCM.

Quantitative Polymerase Chain Reaction (qPCR) and Gene copy number analysis {#S6}
---------------------------------------------------------------------------

QPCR with extracted DNA from LCM procedure was performed on 7300 Real Time PCR System (Applied Biosystems) using Platinum qPCR Supermix-UDG (Invitrogen). For the reaction of 25μl, 12.5μl of 2× Supermix, 1.4μl of water, 0.5μl of ROX reference dye, 1μl each of two 6μM primer pairs (*Pten/Apo B* or *p53/Apo B*), 0.8μl each of two 6μM probes (*Pten/Apo B* or *p53/Apo B*) and 5μl of DNA were added. *Apo B* gene was always coamplified with either *Pten* or *p53* as an internal control. Mouse tail DNA was included in each reaction for normalization. Conditional *Pten* heterozygous and *p53* heterozygous prostate tissues were used as standard samples to determine the range of gene copy number (1 or 0). Triplicate data were analyzed by ddCt method. Based on the range of normalized quantity of standard samples (0.451--0.679 for one copy of *Pten* and 0.276--0.462 for one copy of *p53*, see [Table S1](#SD2){ref-type="supplementary-material"}) as well as significance *t*-test (*P* \< 0.05) between normalized sample quantities and standard sample quantities, gene copy numbers of *Pten* and *p53* were determined. Primers and probes used were: *Pten* forward (5\'-ACA ATC ATg TTg CAg CAA TTC AC-3\'), *Pten* reverse (5\'-CCg ATg CAA TAA ATA TgC ACA AA-3\') and *Pten* probe (5\'-/FAM/CCg gAT g AgC Tgg AAA ggg ACg gAC Tgg TgT AA CAT CCg g/BHQ/-3\'); *Apo B* forward (5\'-ATC TCA gCA CgT ggg CTC-3\'), *Apo B* reverse (5\'-TCA CCA gTC ATT TCT gCC TTT g-3\') and *Apo B* probe (5\'-/JOE/CgC gAT g CCA ATg gTC ggg CAC TgC TCA A CAT CgC g/BHQ/-3\'); *p53* forward (5\'-CTg TgC AgT TgT ggg TCA gC-3\'), *p53* reverse (5\'-ACC TCC gTC ATg TgC TgT gA-3\') and *p53* probe (5\'-/FAM/CCg gAT g ggA gCC gTg TCC gCg CCA T CAT CCg g/BHQ/-3\') (all sequences are available at http://emice-stage.nci.nih.gov/).

Statistical analyses {#S7}
--------------------

Each group was compared using *t*-test or *Chi*-square test ([@R35]). Values are considered statistically significant at *P* \< 0.05. Quantitative variables are expressed as means ± standard deviation while categorical variables are expressed as numbers (%).

Results {#S8}
=======

c-MYC expression sensitizes prostate cells to the effects of loss of one or both copies of the *p53* tumor suppressor gene (TSG) {#S9}
--------------------------------------------------------------------------------------------------------------------------------

Our primary goal was to generate a focal, stepwise model of prostate cancer that closely resembles the human disease and in which we can investigate the relative frequencies of TSG (*Pten* and *p53*) loss at various stages of progression. We have previously shown that focal c-MYC expression in *Pten* heterozygous mice leads to efficient generation of PIN lesions associated with downregulation of Pten protein expression ([@R26]). Progression of these c-MYC+;Pten-negative lesions is restrained by an apoptotic response concurrent with activation of the p53 pathway ([@R26]). To further explore the role of p53 in this model, we first assessed the effects of concurrent loss of *p53* and overexpression of c-MYC. We generated cohorts of conditional, compound mutant mice as follows: *PbCre4;Z-MYC;p53*^*f*/+^ (*c-MYC*+;*p53-het*), *PbCre4;Z-MYC;p53^f/f^* (*c-MYC*+;*p53-ko*), *PbCre4;p53*^*f*/+^ (*p53-het*) and *PbCre4;p53^f/f^* (*p53-ko*), where "het" refers to heterozygous and "ko" refers to knockout. In agreement with a previous report ([@R7]), *p53* deficiency in the mouse prostate by itself did not cause any noticeable abnormalities ([Figures 1](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). However, concurrent c-MYC expression and heterozygous or homozygous *p53* deletion led to the age-dependent development of low grade PIN (LGPIN) and high grade PIN (HGPIN) ([Figures 1](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Some HGPIN lesions in *c-MYC*+;*p53-ko* mice showed evidence of microinvasion but still retained Pten protein expression ([Figure 3B](#F3){ref-type="fig"}). There was an additive increase in proliferation in cells with concurrent reduction of *p53* dosage and c-MYC expression without a significant change in apoptosis ([Figure 3C](#F3){ref-type="fig"}). This contrasts with *c-MYC*+;*Pten-ko* prostates which show elevated rates of apoptosis ([@R26]). Thus c-MYC expression cooperates modestly with *p53* loss in the prostate but the lesions do not rapidly progress to invasive cancer. Notably, we have shown that the level of c-MYC expression in our *c-MYC*+ prostate model is not sufficient to activate the p53 pathway ([@R26]) (see also [Figure S1](#SD4){ref-type="supplementary-material"}), possibly explaining the lack of selective pressure to lose *p53* upon c-MYC expression.

*Pten* and *p53* restrain the progression of c-MYC-initiated prostate cancer {#S10}
----------------------------------------------------------------------------

The results from analysis of *c-MYC*+;*p53*-mutant mice shown above and our previously reported analysis of *c-MYC*+;*Pten*-mutant mice ([@R26]) suggest that retention of wild type *Pten* or *p53* restrains the progression of c-MYC-initiated prostate cancer cells with mutation in either the *p53* or *Pten* TSGs. We sought formal proof of this by examining tumor progression in conditional *c-MYC*+;*Pten/p53* compound mutant mice where only one of either the *Pten* or *p53* alleles is wild type. Indeed, while control *Pten-het;p53-ko* mice without c-MYC overexpression only developed HGPIN with a 33% incidence in mice monitored up to 50 weeks of age ([Figures 1](#F1){ref-type="fig"}, [2B](#F2){ref-type="fig"}, and [4](#F4){ref-type="fig"}), *c-MYC*+;*Pten-het;p53-ko* mice developed aggressive prostate adenocarcinoma as early as 10 weeks of age ([Figures 1](#F1){ref-type="fig"}, [2B](#F2){ref-type="fig"} and [4](#F4){ref-type="fig"}). These tumors were associated with downregulation of the wild type Pten expression ([Figure 4C](#F4){ref-type="fig"}) and were metastatic to the lymph nodes as verified by staining for androgen receptor (AR) and cytokeratin 8 ([Figure 4B](#F4){ref-type="fig"}, panels \`c--e\'). Similarly, *c-MYC*+;*Pten-ko;p53-het* mice developed aggressive prostate adenocarcinoma while the control *Pten-ko;p53-het* mice developed HGPIN and well-differentiated prostate cancer ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [4](#F4){ref-type="fig"}), consistent with the reported phenotype of *Pten-ko* mice ([@R47]). In all cases in these *c-MYC*+;*Pten-het;p53-ko* and *c-MYC*+;*Pten-ko;p53-het* compound mutant mice, development of aggressive tumors was associated with loss of the corresponding wild type *Pten* or *p53* allele as determined by gene copy number assessment using c-MYC and Pten immunofluorescence-guided Laser Capture Microdissection ([Table 1](#T1){ref-type="table"}; see also [Figure 7E](#F7){ref-type="fig"} panels b and c). These results indicate potent synergy between c-MYC expression and loss of *Pten/p53* that appears to be largely mediated by accelerating loss of the wild type *Pten* or *p53* allele. In this regard, it is interesting to note that even in the prostate lesions of *c-MYC*+;*Pten-ko* (i.e. *PbCre4;Z-MYC;Pten^f/f^*) mutant mice, we found evidence for loss of 1 or both copies of the wild type *p53* alleles ([Figure 7E](#F7){ref-type="fig"}, panels "b" and "c" and [Table S2](#SD3){ref-type="supplementary-material"}).

Higher rate of loss of *Pten* compared to *p53* in conditional *c-MYC*+;*Pten-het;p53-het* mice during prostate tumorigenesis {#S11}
-----------------------------------------------------------------------------------------------------------------------------

The heterogeneous focal nature of c-MYC expression in our model provides us with an opportunity to examine, within the same prostate glands, the evolution of PIN lesions to carcinoma and the choice made by incipient neoplastic cells between loss of *Pten* and loss of *p53* during tumor evolution. To facilitate this analysis, we generated and monitored tumor progression in *c-MYC*+;*Pten-het;p53-het* and control *Pten-het;p53-het* mice. In the absence of c-MYC expression heterozygous deletion of *Pten* and *p53* resulted only in PIN with a low penetrance ([Figures 1](#F1){ref-type="fig"}, [2C](#F2){ref-type="fig"} and [5](#F5){ref-type="fig"}). However, in *c-MYC*+;*Pten-het;p53-het* mice with concurrent focal c-MYC expression, we observed focal heterogeneous lesions including PIN, well-differentiated, moderately-differentiated and poorly-differentiated prostate adenocarcinoma ([Figures 1](#F1){ref-type="fig"}, [2C](#F2){ref-type="fig"} and [5](#F5){ref-type="fig"}). The lesions appear to start focally, the neoplastic cells are luminal, AR-positive, without neuroendocrine differentiation and the invasive process is distinctly clear ([Figures 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). Remarkably the PIN and cancer lesions that develop in these animals showed heterogeneous morphology ([Figure 5C](#F5){ref-type="fig"}) suggesting that the lesions contain distinct combinations of genetic abnormalities. Thus this model captures one of the key features of human prostate cancer, i.e. histopathological heterogeneity.

To determine the rates at which *Pten* and *p53* are lost during the progression of these c-MYC-initiated lesions, we used immunofluorescence-guided LCM followed by gene copy number analysis. We stained serial sections from *c-MYC*+;*Pten-het;p53-het* mice for c-MYC, Pten and H&E for LCM ([Figure 7](#F7){ref-type="fig"}). All lesions analyzed demonstrated c-MYC expression. We determined *Pten* and *p53* gene copy numbers by qPCR with DNA isolated following LCM from a total of 60 PIN and cancer foci ([Tables 1](#T1){ref-type="table"} and [S1](#SD2){ref-type="supplementary-material"}). Overall, *Pten* copy loss was observed in 60% of the PIN and cancer lesions while *p53* was lost in 40% of the lesions ([Table 1](#T1){ref-type="table"}, [Figure 7E](#F7){ref-type="fig"}). Notably, the rate of *Pten* copy number loss is significantly higher than that of *p53* loss in PIN lesions (50% vs. 29.2%), while cancer lesions showed equivalent rates of *Pten* and *p53* loss ([Table 1](#T1){ref-type="table"}, [Figure 7D](#F7){ref-type="fig"}). Furthermore, samples with *p53* loss were subsumed in those with *Pten* loss with two exceptions (samples S35 and S76 in [Table 1](#T1){ref-type="table"}). These results indicate a higher rate of *Pten* loss compared to *p53* loss during mouse prostate tumor progression.

We were also able to correlate loss of Pten protein expression in the same prostatic glands to loss of *Pten* copy number ([Figure 7A, B](#F7){ref-type="fig"}). There were more lesions with loss of Pten expression than with *Pten* loss of copy number ([Figure 7B](#F7){ref-type="fig"}). Thus, only 70.6% (36/51) of the lesions with loss of Pten expression showed evidence for loss of *Pten* copy number as well ([Figure 7B](#F7){ref-type="fig"}). For example, in [Figure 7A](#F7){ref-type="fig"}, while both lesions S3 and S4 displayed loss of Pten expression, only S4 also showed loss of *Pten* gene copy. While it is difficult to completely exclude the possibility of stromal contamination of LCM material, these results may also indicate the fact that loss of Pten protein precedes genetic loss of *Pten* DNA, through epigenetic mechanisms including promoter methylation ([@R9]; [@R46]) or post-transcriptional/-translational control of Pten mRNA/protein ([@R38]).

Discussion {#S12}
==========

Our model of prostate cancer based on conditional focal c-MYC expression in the mouse prostate epithelium recapitulates several salient aspects of the human disease. First, all the three genes we focused on, i.e. *c-MYC*, *Pten* and p*53* are frequently involved in human prostate cancer, with c-MYC overexpression being the most early and most frequent alteration of the three genes ([@R22]; [@R43]). Second, c-MYC+ cells in this model expand over time to form a field of histologically normal, c-MYC-overexpressing cells that are sensitized to the effects of further tumorigenic mutations, specifically loss of one or both alleles of *Pten* or *p53*. The fact that histologically normal-appearing tissue may harbor cancer-promoting alterations raises questions about the appropriateness of using so-called "normal adjacent prostate" as a control in molecular studies aimed at deciphering differences between cancer and normal tissues. Third, in the *c-MYC*+;*Pten-het;p53-het* model, PIN and cancer lesions arise focally and are histologically heterogeneous, even within the same glands. This most likely reflects the genetic heterogeneity of lesions, as *c-MYC*+;*Pten*-deficient lesions are histologically quite distinct from *c-MYC*+;*p53*-deficient lesions. Fourth the tumors that arise in this model are adenocarcinomas like the majority of human prostate cancers, retaining androgen receptor expression with no evidence of significant neuroendocrine differentiation.

The *c-MYC*+;*Pten-het;p53-het* model provided a unique opportunity to examine the rate at which distinct TSGs are lost during prostate tumor progression. The heterozygosity in *Pten* and *p53* facilitates analysis of TSG pathway inactivation, making it more likely that the tumors will select loss of the wild type TSG allele as a means of inactivating the pathway, rather than mutations in other components of the pathway that may have the same functional outcome. Indeed, our finding that advanced tumors in this model uniformly show loss of *Pten* and *p53* genes validates this approach. In human tumors, evidence for a preferred order in which mutations in cancer genes develop during clonal progression have been deduced by examining the mutation frequencies for various genes at different stages of tumor progression and the rate in which mutations in specific genes co-occur ([@R15]); ([@R50]).

Using, LCM we examined a large number of PIN and cancer lesions for status of the wild type *Pten* and *p53* alleles in *c-MYC*+;*Pten-het*;*p53-het* mice and found clear evidence for a preference for the loss of *Pten* prior to *p53*. Examination of human samples supported with this conclusion. These results indicate that while the mutations involved in tumor initiation may arise stochastically, the nature of the subsequent genetic alterations selected for during clonal evolution may be constrained by the nature of the preceding mutation. Thus, c-MYC overexpressing cells tend to lose *Pten* over *p53* because loss of *Pten* provides greater selective advantage to the tumor cell than *p53* loss ([Figure 8](#F8){ref-type="fig"}). Additionally, c-MYC overexpression in our model does not activate p53, meaning there is no pressure on the c-MYC+ cells to inactivate the p53 pathway. Once *Pten* is lost however, the p53 pathway is strongly activated ([@R7]; [@R26]). In the context of c-MYC overexpression in our model, we have shown that the p53 response is shifted from senescence to apoptosis because c-MYC represses the p53 target gene *p21^Cip1^* ([@R26]). Thus Pten loss, even though it provides several advantages to the tumor cell also activates a tumor-restraining barrier in the form of p53 activation. This provides selective pressure for inactivation of *p53*. Indeed we found that advanced prostate cancers in *c-MYC*+;*Pten-het*;*p53-het* mice show almost uniform evidence of loss of the wild type *p53* allele.

It is important to point out that our Z-MYC model differs from other prostate-Myc transgenic models that have been analyzed. For example, De Marzo and colleagues ([@R24]) recently analyzed Lo-Myc and Hi-Myc transgenic mice developed by the Sawyers group ([@R14]) and deduced that MYC overexpression leads to an immediate change in cellular morphology consistent with transformation. We do not see a similar effect in our prostate Z-MYC model, possibly due to differences in expression level or genetic strain differences.

Our study has not directly addressed the cell of origin of the tumors in this model. Our previous analysis of the *PBCre4*;*Z-MYC* model has shown that c-MYC is induced focally in the prostatic luminal epithelial cell compartment ([@R26]). The specific identity of the cell of origin of the tumors that develop in this model awaits further study. Nonetheless, it may be possible, once the rules governing the timing and rate at which mutations occur during tumor progression are understood, to exploit them in individualized chemopreventive or therapeutic strategies to the detriment of the tumor cell. For example, *c-MYC*+;*Pten*-deficient tumor cells are under pressure to avoid a strong p53-dependent apoptotic response, and this knowledge could be exploited. Such efforts will be crucially dependent on the use of accurate *in vivo* models of human cancer like the *c-MYC*+;*Pten-het*;*p53-het* mouse model described here.
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![Summarized pathology of mouse prostates with alterations in *c-MYC*, *Pten* and/or *p53*\
Pathology summary of prostate-specific, conditional mouse models of prostate cancer with alterations in *c-MYC*, *Pten* and/or *p53*, based on this report and three published studies ([@R7]; [@R26]; [@R47]). The pathological diagnoses are indicated with solid colors when they occur with 100% incidence; otherwise, shown as gradient colors. All the reports utilized the same prostate-specific *Cre* line (*PbCre4*, ([@R49])). Het = conditional heterozygous mutant, ko = conditional knockout, N/S = numbers not specified.](nihms-293395-f0001){#F1}

![Summary of pathology of mouse prostates\
Graphs show histopathology findings in each group of mutant mouse prostates. Genotypes, the number of mice (N) examined and ages (in weeks) when analyzed are indicated.](nihms-293395-f0002){#F2}

![Modest cooperation between focal c-MYC expression and *p53* haploinsufficiency or deficiency in the mouse prostates\
(A and B) H&E images showing the pathology in mutant mouse prostates. Note focal high grade PIN in *c-MYC*+;*p53-het* mouse prostates (\`c\' and \`d\' in A) and PIN with microinvasion (arrows) in *c-MYC*+;*p53-ko* prostate (\`a\' and \`d\' in B). Note breach in SMA, smooth muscle actin indicative of microinvasion in \`b\' and \`e\'. Panels \`c\' and \`f\' in B show Pten expression by immunofluorescence. Scale bars: 100μm. (C) Cellular proliferation and apoptosis in the mouse prostates are quantitated following immunohistochemistry for phospho-histone H3 (pHH3) and activated Caspase 3, respectively. N=3--5 per group. \**P* \< 0.05.](nihms-293395-f0003){#F3}

![Additional deletion of either one or two copies of *Pten* accelerates tumor formation and leads to lymph node metastases\
(A) H&E stains. Examples of rare, focal HGPIN in old *Pten-het*;*p53-ko* mouse prostate (age=50 weeks) are shown in panels \`a--d\'. (B) H&E stains of sections from *c-MYC*+;*Ptenhet*;*p53-ko* mice show aggressive cancers (panels \`a\' and \`b\') with lymph node metastases (panels \`c--e\'). \`c,d,e\' show H&E, staining for androgen receptor (AR) and cytokeratin 8 (CK8) in lymph node (insets are higher magnification images). (C) Immunofluorescent detection of focal (a) or diffuse (b) loss of Pten expression (arrows) in mice with the indicated genotypes. (D) H&E stained sections show HGPIN/well-differentiated cancer and moderately-differentiated cancer in *Pten-ko*;*p53-het* (a) and *c-MYC*+;*Pten-ko*;*p53-het* (b) mouse prostates, respectively. Scale bars: 100μm.](nihms-293395-f0004){#F4}

![*c-MYC*+;*Pten-het*;*p53-het* mice develop heterogeneous prostate cancer\
(A) Gross images of prostates of *Pten-het*;*p53-het* (a) and *c-MYC*+;*Pten-het*;*p53-het* (b) mice. (B) H&E stains show representative pathology of the mouse prostates. Note that only older (33--46 weeks) *Pten-het*;*p53-het* mouse prostates developed mPIN lesions (arrows in \`a\') while focal invasive (arrow in \`b\') or poorly differentiated cancer developed in *c-MYC*+;*Pten-het*;*p53-het* mouse prostates. Inset in \`b\' shows high power image of focal invasion. (C) Heterogeneity in mPIN/cancer lesions of *c-MYC*+;*Pten-het*;*p53-het* mouse prostates. Note lesions marked with arrows and arrowheads showing distinct histology. (\`b\' and \`c\' are enlarged portions of the gland shown in \`a\' while \`e\' and \`f\" are enlarged portions of gland shown in \`d\'). Scale bars: 1cm in "A", 100μm in "B" and "C".](nihms-293395-f0005){#F5}

![Androgen receptor and synaptophysin expression in mouse prostate tumors\
*Top*, Androgen receptor, (AR) expression is present as brown nuclear and nuclear/cytoplasmic staining in mutant mouse prostate tumors. Control is a sample without primary antibody. *Bottom*, Neuroendocrine marker synaptophysin expression (brown) is grossly absent in mouse prostate tumors. Control is a MYC/Pim1-expressing tumor used as a positive control. Scale bars, 100μm.](nihms-293395-f0006){#F6}

![A preference for loss of *Pten* prior to loss of *p53* in c-MYC-initiated mouse prostate cancer\
(A and C) Adjacent sections from *c-MYC*+;*Pten-het*;*p53-het* mouse prostates were stained for Pten/SMA, Hematoxylin (H) or c-MYC. PIN and cancer foci were microdissected by LCM and DNA isolated. Arrows indicate microdissected glands. Lesions S3 and S4 (e) both have loss of Pten protein expression but only S4 shows loss of *Pten* DNA copy number. Scale bars: 500μm. (B) Graph showing percent loss of Pten protein expression in abnormal prostatic lesions (N = 60 lesions, including 48 PINs and 12 cancers) analyzed (\`a\', black bar) and percent of lesions that also lost the wild type *Pten* DNA copy (N = 51) (\`b\', black bar). (D) Comparison of the frequency of loss of *Pten* or *p53* wild type alleles. Note that *Pten* loss is significantly more frequent than *p53* loss in PIN but not cancer lesions. \**Chi*-square test, *P* \< 0.05. (E) Heatmap representations of loss of either *Pten* or *p53* loss (black bars) in each sample (PIN and cancer) based on the copy number analysis in [Table 1](#T1){ref-type="table"}. Boxes under the black line indicate cancer samples, while the remaining samples are PIN. Number of microdissected lesions analyzed: *c-MYC*+;*Pten-het*;*p53-het,* N=60. *c-MYC*+;*Pten-het*;*p53-ko*, N=9 and *c-MYC*+;*Pten-ko*;*p53-het*, N=5.](nihms-293395-f0007){#F7}

![Model for loss ofn *Pten* and *p53* in c-MYC-initiated prostate cancer\
c-MYC expression in the prostatic epithelium provokes a mild increase in proliferation and apoptosis. A majority of the c-MYC-expressing cells show no histological abnormality. At this stage, the p53 pathway is not activated. Next, c-MYC-expressing cells preferentially lose the *Pten* tumor suppressor leading to increased proliferation and progression to cancer. However, at this stage apoptosis is also evident due to activation of p53 pathway upon *Pten* loss. Selective pressure to avoid apoptosis promotes loss of *p53*, allowing cells to overcome apoptosis, resulting in development of aggressive prostate cancer.](nihms-293395-f0008){#F8}

###### 

Pten expression status and gene copy number quantitation of *Pten* and *p53* in mutant mouse prostate samples.

  Mouse ID (age)                  Sample \#   Pathology   Pten IHC   *Pten* Copy \#                      Normalized Qty (*Ren*)   *p53* Copy \#                       Normalized Qty (*p53*)
  ------------------------------- ----------- ----------- ---------- ----------------------------------- ------------------------ ----------------------------------- ------------------------
  ***c-MYC+;Pten-het;p53-ko***                                                                                                                                        
                                                                                                                                                                      
  7352 (16wks)                    S55         PIN         \-         0                                   0.1156                   0[\*](#TFN1){ref-type="table-fn"}   ND
                                  S56         PIN         \-         0                                   0.2928                   0[\*](#TFN1){ref-type="table-fn"}   ND
                                  S58         Cancer      \-         0                                   0.0446                   0[\*](#TFN1){ref-type="table-fn"}   ND
                                                                                                                                                                      
  7345 (17wks)                    S52         PIN         \-         0                                   0.1534                   0[\*](#TFN1){ref-type="table-fn"}   ND
                                  S53         PIN         \-         0                                   0.2352                   0[\*](#TFN1){ref-type="table-fn"}   ND
                                  S54         Cancer      \-         0                                   0.007                    0[\*](#TFN1){ref-type="table-fn"}   ND
                                                                                                                                                                      
  151 (19wks)                     S51         PIN         \+         1                                   0.6712                   0[\*](#TFN1){ref-type="table-fn"}   ND
                                  S49         PIN         \-         0                                   0.1732                   0[\*](#TFN1){ref-type="table-fn"}   ND
                                  S50         Cancer      \-         0                                   0.1482                   0[\*](#TFN1){ref-type="table-fn"}   ND
                                                                                                                                                                      
  ***c-MYC+;Pten-ko;p53-het***                                                                                                                                        
                                                                                                                                                                      
  547 (16wks)                     S70         PIN         ND         0[\*](#TFN1){ref-type="table-fn"}   ND                       0                                   0.2315
                                  S69         Cancer      ND         0[\*](#TFN1){ref-type="table-fn"}   ND                       0                                   0.098
                                                                                                                                                                      
  593 (18wks)                     S100        PIN         ND         0[\*](#TFN1){ref-type="table-fn"}   ND                       1                                   0.3003
                                  S101        PIN         ND         0[\*](#TFN1){ref-type="table-fn"}   ND                       1                                   0.4117
                                  S102        PIN         ND         0[\*](#TFN1){ref-type="table-fn"}   ND                       1                                   0.2942
                                                                                                                                                                      
  ***c-MYC+;Pten-het;p53-het***                                                                                                                                       
                                                                                                                                                                      
  7312 (10wks)                    S19         PIN         \-         0                                   0.0015                   0                                   0.0448
                                                                                                                                                                      
  8150 (16wks)                    S1          Cancer      \-         0                                   0.3333                   1                                   0.5797
                                  S2          PIN         \-         1                                   0.6062                   1                                   0.6318
                                  S3          PIN         \-         1                                   0.6087                   1                                   0.7103
                                  S4          Cancer      \-         0                                   0.3283                   1                                   0.5631
                                  S5          PIN         \+         1                                   0.9152                   1                                   0.7202
                                  S6          PIN         \+         1                                   1.0263                   1                                   0.5593
                                  S7          PIN         \+         1                                   0.9161                   1                                   0.6605
                                  S8          PIN         \+         1                                   1.0027                   1                                   0.5276
                                  S10         PIN         \+         1                                   1.3528                   1                                   0.9262
                                                                                                                                                                      
  561 (17wks)                     S96         PIN         \-         1                                   0.483                    1                                   0.4282
                                  S97         PIN         \-         1                                   0.5407                   1                                   0.4322
                                  S98         PIN         \-         0                                   0.3992                   1                                   0.3146
                                  S99         PIN         \-         0                                   0.4241                   1                                   0.3983
                                                                                                                                                                      
  355 (18wks)                     S83         PIN         \-         0                                   0.3536                   1                                   0.3051
                                  S84         PIN         \-         1                                   1.6025                   1                                   0.3974
                                                                                                                                                                      
  243 (23wks)                     S82         PIN         \-         0                                   0.3355                   0                                   0.236
                                                                                                                                                                      
  8184 (24wks)                    S11         PIN         \-         0                                   0.2316                   1                                   0.751
                                  S12         PIN         \-         1                                   0.9762                   1                                   0.6265
                                  S13         PIN         \-         1                                   0.8407                   1                                   0.6842
                                  S14         PIN         \-         1                                   0.7727                   1                                   0.7652
                                  S15         PIN         \-         1                                   0.7679                   1                                   0.701
                                  S16         PIN         \-         1                                   0.6586                   1                                   0.7117
                                  S17         PIN         \-         1                                   0.5308                   1                                   0.7464
                                  S78         PIN         \-         0                                   0.2545                   0                                   0.157
                                  S79         PIN         \-         0                                   0.2557                   1                                   0.3114
                                  S80         PIN         \-         0                                   0.2463                   1                                   0.3972
                                  S81         Cancer      \-         0                                   0.3272                   0                                   0.2112
                                                                                                                                                                      
  7367 (26wks)                    S28         PIN         \+         1                                   0.4922                   1                                   0.32
                                  S29         PIN         \-         1                                   0.5657                   1                                   0.483
                                  S30         PIN         \-         0                                   0.3419                   0                                   0.1239
                                  S31         PIN         \-         0                                   0.3549                   0                                   0.2659
                                  S32         PIN         \-         0                                   0.2626                   1                                   0.3308
                                  S34         PIN         \-         1                                   0.552                    1                                   0.3014
                                  S35         PIN         \+         1                                   0.7529                   0                                   0.2411
                                  S36         PIN         \-         0                                   0.4428                   1                                   0.3726
                                  S38         PIN         \+         1                                   0.5998                   1                                   0.3149
                                  S39         PIN         \-         0                                   0.4191                   1                                   0.2928
                                  S41         PIN         \+         1                                   0.4396                   1                                   0.4553
                                  S42         PIN         \-         0                                   0.3313                   1                                   0.6036
                                  S76         PIN         \-         1                                   0.3464                   0                                   0.2705
                                  S77         PIN         \-         0                                   0.3299                   0                                   0.2451
                                                                                                                                                                      
  411 (27wks)                     S93         PIN         \-         1                                   0.4076                   1                                   0.3423
                                  S94         PIN         \-         0                                   0.4472                   1                                   0.3562
                                  S95         PIN         \-         0                                   0.4099                   1                                   0.3082
                                                                                                                                                                      
  7379 (38wks)                    S43         Cancer      \-         0                                   0.0376                   0                                   0.0159
                                  S44         Cancer      \-         0                                   0.0168                   0                                   0.0078
                                  S45         Cancer      \-         0                                   0.0815                   0                                   0.018
                                  S47         PIN         \-         0                                   0.2102                   0                                   0.1327
                                                                                                                                                                      
  8409 (39wks)                    S22         Cancer      \-         0                                   0.0001                   0                                   0.1290
                                  S23         Cancer      \-         0                                   0.0009                   0                                   0.0690
                                  S24         Cancer      \-         0                                   0.0003                   0                                   0.0691
                                  S25         Cancer      \-         0                                   0.1867                   0                                   0.2615
                                                                                                                                                                      
  109 (40wks)                     S86         PIN         \-         0                                   0.2649                   0                                   0.2491
                                  S87         PIN         \-         0                                   0.0777                   0                                   0.0779
                                  S88         Cancer      \-         0                                   0.0054                   0                                   0.0076
                                  S89         Cancer      \-         0                                   0.0348                   0                                   0.0223
                                  S90         PIN         \-         0                                   0.1058                   0                                   0.0563
                                  S91         PIN         \-         0                                   0.0825                   0                                   0.0771
                                  S92         PIN         \-         0                                   0.1826                   0                                   0.1242

Gene copy number was determined by qPCR of DNA isolated from immunofluorescence-guided microdissected PIN and cancer lesions.

Copy number based on genotype. ND = not determined. Wks = weeks. IHC=immunohistochemistry.
